TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe chronic plaque psoriasis who receive a new prescription for alefacept~Exclusion Criteria:~* Subjects with a contraindication to alefacept~* Subjects with a history of cancer except for adequately treated basal cell carcinoma (maximum of 2 lesions)~* Subjects with any active cancer, including skin cancer~* Subjects having a serious local infection (eg. cellulitis, abscess) or serious systemic infection (eg. pneumonia, septicemia, tuberculosis), within the 3 months prior to the first dose of alefacept.~* Subjects known to be infected with the AIDS virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Amevive Exposure (Type: None): Canadian subjects with moderate to severe chronic plaque psoriasis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: SMS-based Lifestyle Intervention for Patients With Liver Cirrhosis With Previous Hepathic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult, i.e. age 18 years or above.~2. Is attending the liver cirrhosis rehabilitation clinic at Bispebjerg hospital; i.e., has alcohol-induced liver cirrhosis or hepatorenal syndrome and has at least once experienced severe decompensation in the form of hepatic encephalopathy or variceal haemorrhage.~3. Has attended at least 50% of the scheduled sessions in the 12 week run-in physical exercise program~4. Is the owner of a mobile phone capable of receiving SMS-messages~5. Has signed informed consent~6. Reads and speaks Danish~Exclusion Criteria:~1. Any condition that in the opinion of the investigator puts an otherwise eligible participant at increased risk by participation or otherwise make the person unfit for participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: ACTIVE_COMPARATOR): 12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
- SMS-messages (Type: EXPERIMENTAL): 12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males and females age 18 - 64 years of age~2. District Attorney-approved DUI Court participants within 3 months of enrollment into DUI Court~3. Currently meets DSM-IV criteria for alcohol dependence~4. Subject agrees to alcohol abstinence as a goal~5. Women must agree to use an approved method of birth control (tubal ligation, birth control pills, IUD)~6. Negative UCG (females only)~7. Treatment with an MAOI, other antidepressants, antipsychotics, anticonvulsants, mood stabilizers, or Saint John's Wort are permissible if subject has been on a stable dose for 3 months~8. Must have the ability to comprehend key components of the informed consent and provide consent~9. Current score of 15 or less on the Beck Depression Inventory II~10. Subject has undergone detoxification and is currently abstinent from alcohol~Exclusion Criteria:~1. History of allergy to acamprosate~2. Previously failed trial of acamprosate~3. Pregnancy, lactation, or unprotected intercourse during study period~4. Lifetime diagnosis of schizophrenia or schizoaffective disorder~5. Creatinine clearance \<30 mL/minute. If serum creatinine is greater than 1.4 mg/dL then the Cockcroft-Gault equation will be used to estimate creatinine clearance~6. Active suicidality, a Beck Depression Inventory II suicide item score of \> 2, or a Beck Depression Inventory II total score \> 15~7. Any unstable medical condition which, in the opinion of the investigator, is considered clinically significant or could affect the subject's safety or ability to complete the study~8. Use of a benzodiazepine or other sedative-hypnotic agent (including kava kava or valerian), except for eszopiclone, zaleplon, or zolpidem \< 3 times weekly over the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- DUI Court Participants (Type: EXPERIMENTAL): Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing major head and neck surgery with concomitant free flap reconstruction surgery at UCDMC (oncology and non-oncologic): There will be two groups. Group 1 will include reconstruction with fibula free flap only. Group 2 will include any other free flap reconstruction, including scapular free flap, radial forearm free flap, anterolateral thigh free flap, anteromedial thigh free flap, and latissimus dorsi free flap.~* Patients naïve to gabapentin~* Adult patients \>18 years of age and able to consent~Exclusion Criteria:~* Patients who are already taking scheduled gabapentin~* Patients allergic to gabapentin~* Chronic opioid use not from active head and neck cancer~* Illicit drug use (per report)~* Patients with known renal compromise, such that Creatinine clearance is \< 30~* Patient with known hepatic insufficiency or cirrhosis~* Adults unable to consent~* Individuals less than 18 years old~* Pregnant women~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
- Intervention (Type: EXPERIMENTAL): Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Age 40 or older.~* Positive diagnostic imaging of the affected shoulder indicating full thickness Massive RCT (according to Cofield classification) or long involving more than one tendon.~* Persistent pain and functional disability of the affected shoulder for at least 3 months.~Main Exclusion Criteria :~* Known allergy to the balloon material (copolymer of PLA and -θ-caprolactone).~* Evidence of significant osteoarthritis or cartilage damage in the shoulder~* Evidence of gleno-humeral instability~* Previous surgery of the shoulder in the past 2 years, excluding diagnostic arthroscopy~* Evidence of major joint trauma, infection, or necrosis in the shoulder~* Partial-thickness tears of the rotator cuff

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Best Repair of torn Rotator Cuff (Type: SHAM_COMPARATOR): Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
- InSpace™ system (Type: ACTIVE_COMPARATOR): Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females, 18 years of age or older~2. Currently intubated and mechanically-ventilated subjects in the ICU~3. Suspicion of lower respiratory tract infection~4. Presence of Gram-negative organism(s) by Gram stain OR by culture of pre-therapy respiratory specimen (eg, endotracheal aspirate \[ETA\], bronchoalveolar lavage \[BAL\], or mini-BAL) OR previous colonization 48 h before screening.~5. Initial empiric antimicrobial meropenem regimen~6. At least two risk factors for multidrug-resistant organisms~7. Provision of written informed consent by the subject or a family member or a close relative or waiver of consent.~Exclusion Criteria:~1. Subjects who have received antibiotic therapy for Gram-negative LRT infection for ≥ 36 hours at the time of randomization~2. Subjects with known or suspected type 1 hypersensitivity to beta-lactam and/or cephalosporin~3. Subjects taking valproic acid for a seizure disorder~4. Subjects who have had a left hemisphere stroke within five days and there is an increased risk of fatal brain oedema~5. Subjects who have cystic fibrosis, human immunodeficiency virus (HIV) infection with CD4 count \<100 cell/mm3 or invasive fungal infection of the lung~6. Neutropenia (ANC \< 103 neutrophils/mm3)~7. Bone marrow transplant.~8. Subjects who have been on mechanical ventilation for \>28 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: MON4STRAT Strategy (Type: EXPERIMENTAL): None
- Group 2: Conventional treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ESCAPE Migraine Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Patient must be between the ages of 18 and 70;~* Patient must have a migraine history and demonstrate a refractoriness to medical treatment;~* Patient must have a Patent Foramen Ovale (PFO);~* Patient must be willing and able to give informed consent and complete required follow-up visits.~Major Exclusion Criteria:~* Patient has any medical condition or receives any medication that would preclude participation in the trial~* Patient is enrolled or intends to participate in another clinical study (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the study or within four weeks prior to his/her enrollment in the study.~* Patient is pregnant, or intends to become pregnant during the trial period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Test Arm with Premere investigational (Type: ACTIVE_COMPARATOR): PFO Closure with Premere investigational device.
- Medical management/current medications (Type: ACTIVE_COMPARATOR): Patients in the control group arm will not receive the medical device and will continue medical management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven recurrent or refractory pediatric solid tumor~* Bone marrow metastases allowed~PATIENT CHARACTERISTICS:~Age:~* 1 to 30~Performance status:~* 0-2~Life expectancy:~* At least 2 months~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm3~* Platelet count at least 100,000/mm3 (transfusion independent)~* Hemoglobin at least 10 g/dL (RBC transfusion allowed)~Hepatic:~* Bilirubin no greater than 1.5 times normal~* SGOT no greater than 2.5 times normal~Renal:~* Adequate renal function as defined by one of the following:~  * GFR by creatinine clearance~ * Radioisotope GFR~ * Iothalamate at least 70 mL/min~Cardiovascular:~* Adequate cardiac function as defined by one of the following:~  * Ejection fraction at least 55% by MUGA~ * Fractional shortening at least 28% by echocardiogram~Neurologic:~* Adequate CNS function as defined by:~  * Seizure disorder, if present, controlled by anticonvulsants~ * CNS toxicity no greater than grade 2~Other:~* No uncontrolled infections~* Not pregnant or nursing~* No allergy to platinum compounds~* No history of allergy to etoposide (unless mobilization phase not required)~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Recovered from prior immunotherapy~* At least 1 week since prior cytokines~* At least 3 months since prior bone marrow or peripheral blood stem cell transplantation~* No concurrent immunomodulator~* No concurrent cytokines~Chemotherapy:~* At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered~* No prior thiotepa~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* Recovered from prior radiotherapy~* At least 6 months since prior total body irradiation conditioning~* No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effect of Sodium Intake Reduction in Treatment Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* individuals who agreed to participate in the study and submitted written informed consent~* individuals aged 20 or more years~* Hypertensive patients whose blood pressure is not controlled normally while taking three or more antihypertensive agents including diuretics~* Diuretics should be Hydrochlorothiazide or Indapamide~Exclusion Criteria:~* Systolic blood pressure ≥ 220 mmHg~* Chronic kidney disease: estimated Glomerular filtration rate by Modification of Diet in Renal Disease formula ≤ 30 mL/min~* Hyperkalemia (\>5.5 mmol/L) or hypokalemia (\<3.5 mmol/L)~* Hyponatremia (\<135 mmol/L)~* Major cardiovascular events (MI, unstable angina, coronary revascularization, stroke) within 6 month of screening~* Retinal bleeding within 3 months~* Heart failure stage 3 or 4~* Severe liver disease~* Pregnancy or women in the fertile age not using efficient contraceptive methods~* Alcoholism~* Renovascular disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium intake reduction and exercise (Type: ACTIVE_COMPARATOR): education of sodium intake reduction and regular exercise
- Exercise (Type: PLACEBO_COMPARATOR): education of regular exercise only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypothermia in Children After Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a GCS \</= 8~2. Glasgow Motor Score \< 6~3. Closed head injury~4. Age 0 \< 18 y~Exclusion Criteria~1. Unavailable to initiate cooling within 6 hours of injury~2. Glasgow Coma Scale (GCS) score = 3 and abnormal brainstem function~3. Normal initial CT scan (No blood, fracture, swelling, and/or shift)~4. Penetrating brain injury~5. No known mechanism of injury~6. Unknown time of injury~7. Uncorrectable coagulopathy (PT/PTT \> 16/40 sec, INR \> 1.7)~8. Hypotensive episode (Systolic Blood Pressure \<5th percentile for age\>10 min)~9. Documented Hypoxic episode (O2 saturation \< 94% for \> 30 min)~10. Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Induced moderate hypothermia (32-33 C)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Knee Osteoarthritis Care: A Quality Improvement Intervention in Physiotherapists

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with knee osteoarthritis, treated by a participating physiotherapist within a predefined period~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention= education peer review group (Type: OTHER): For this controlled trial a group of physiotherapists will recieve specific education about optimal exercise therapy for patioents with knee OA in early stage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Open-Label Pilot Study of V3381 in Chronic Cough

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18-75 years of age~* Females must be of non child-bearing potential~* Chronic Cough ( \> 8 weeks)~* Normal Chest X-ray~* Normal Lung Function~* Idiopathic or treatment resistant cough-~Exclusion Criteria:~* Recent upper respiratory tract infection (\<4 weeks)~* Pregnancy/breast-feeding~* Current smokers or ex-smokers with \<6 months abstinence or cumulative history of \>10 pack years~* Current treatment with ACE inhibitors.~* Drug or alcohol abuse~* Uncontrolled hypertension (i.e., \>140/90 mmHg despite adequate medical therapy).~* Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina).~* Any clinically significant neurological disorder~* Prior renal transplant, current renal dialysis.~* Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study.~* Increased risk of seizures.~* Any malignancy in the past 2 years (with the exception of basal cell carcinoma).~* Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).~* Any clinically significant abnormal laboratory test result(s).~* Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance \<60 mL/min.~* Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's Syndrome) and/or alanine transaminase (ALT) \>1.5 times upper limit of normal reference ranges (after adjustment for age).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Association Between a Biological Pattern of Dysregulation of the HPA Axis and Mental Disorders in Children Exposed to Early Life Stress

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 8 to over 10 years~* To be entrust to ASE of Finistère in stable environment (the same place of residence since 6 months or more)~* French speaking~* Oral consent by children~* Informed and signed consent by tenured of parent authority~Exclusion Criteria:~* Don't want to participate~* To have chronic neurologic or endocrinal pathology or don't have access to verbal language.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- study with just one arm (Type: OTHER): All of participants are in this arm. Mini Kid II and CBCL score are administered between day 3 and 7. Moreover, salivary test will be remove to evaluate cortisol secretion, 4 time per day during 2 consecutive days.~Psychologic aftercare will be propose if children have psychologic troubles (results of Mini Kid II)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues